Ampicillin-Loaded Fenugreek-Derived Exosomes Treat COPD via Anti-Inflammatory, Antibacterial and Anti-Fibrotic Effects - PubMed
3 hours ago
- #Ampicillin
- #COPD
- #Exosomes
- Ampicillin-loaded fenugreek-derived exosomes (Exos-AM) developed as a novel treatment for COPD.
- Exos-AM combines anti-inflammatory, antibacterial, and anti-fibrotic effects to address COPD progression.
- Plant-derived exosomes offer advantages like low immunogenicity, natural abundance, and easy isolation.
- In vitro, Exos-AM showed antibacterial activity against S. aureus, E. coli, and P. aeruginosa.
- Exos-AM promotes macrophage polarization to the anti-inflammatory M2 phenotype, reducing inflammation and fibrosis.
- Transcriptomic analysis revealed Exos-AM suppresses NF-κB and MAPK pathways, explaining its anti-inflammatory effects.
- In vivo, Exos-AM improved lung histopathology and enhanced bacterial clearance in a murine COPD model.
- The study highlights plant-derived exosomes as versatile drug delivery platforms for COPD treatment.